Guillaume Drui

417 total citations
7 papers, 323 citations indexed

About

Guillaume Drui is a scholar working on Cellular and Molecular Neuroscience, Neurology and Cognitive Neuroscience. According to data from OpenAlex, Guillaume Drui has authored 7 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cellular and Molecular Neuroscience, 5 papers in Neurology and 3 papers in Cognitive Neuroscience. Recurrent topics in Guillaume Drui's work include Parkinson's Disease Mechanisms and Treatments (5 papers), Neurotransmitter Receptor Influence on Behavior (4 papers) and Neurological disorders and treatments (3 papers). Guillaume Drui is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (5 papers), Neurotransmitter Receptor Influence on Behavior (4 papers) and Neurological disorders and treatments (3 papers). Guillaume Drui collaborates with scholars based in France, Switzerland and Canada. Guillaume Drui's co-authors include Carole Carcenac, M. Favier, Marc Savasta, Sébastien Carnicella, Sabrina Boulet, Anne Bertrand, Yosuke Saga, Léon Tremblay, Benjamin Pasquereau and Élise Météreau and has published in prestigious journals such as Scientific Reports, Neuropsychopharmacology and Molecular Psychiatry.

In The Last Decade

Guillaume Drui

7 papers receiving 321 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guillaume Drui France	7	197	172	74	50	34	7	323
Yvan M. Vachez France	11	107 0.5×	180 1.0×	72 1.0×	57 1.1×	26 0.8×	14	310
Jérôme Lerond France	7	103 0.5×	94 0.5×	89 1.2×	60 1.2×	46 1.4×	8	328
K. Wu United Kingdom	6	336 1.7×	174 1.0×	81 1.1×	18 0.4×	35 1.0×	8	432
Susie Turkson United States	6	142 0.7×	130 0.8×	53 0.7×	59 1.2×	47 1.4×	10	330
Sarah M. Fayad United States	7	251 1.3×	101 0.6×	88 1.2×	25 0.5×	80 2.4×	8	345
J. Ding China	4	116 0.6×	127 0.7×	23 0.3×	85 1.7×	34 1.0×	7	324
Heiko Huber Germany	10	225 1.1×	153 0.9×	111 1.5×	64 1.3×	60 1.8×	12	450
Nora Vanegas United States	4	153 0.8×	125 0.7×	71 1.0×	20 0.4×	20 0.6×	4	305
C Soubrouillard France	6	207 1.1×	162 0.9×	63 0.9×	69 1.4×	10 0.3×	8	360
Akinori Futamura Japan	9	87 0.4×	57 0.3×	99 1.3×	33 0.7×	37 1.1×	49	303

Countries citing papers authored by Guillaume Drui

Since Specialization

Citations

This map shows the geographic impact of Guillaume Drui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillaume Drui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillaume Drui more than expected).

Fields of papers citing papers by Guillaume Drui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guillaume Drui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillaume Drui. The network helps show where Guillaume Drui may publish in the future.

Co-authorship network of co-authors of Guillaume Drui

This figure shows the co-authorship network connecting the top 25 collaborators of Guillaume Drui. A scholar is included among the top collaborators of Guillaume Drui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillaume Drui. Guillaume Drui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Pasquereau, Benjamin, Guillaume Drui, Yosuke Saga, et al.. (2021). Selective serotonin reuptake inhibitor treatment retunes emotional valence in primate ventral striatum. Neuropsychopharmacology. 46(12). 2073–2082. 7 indexed citations

2.

Pasquereau, Benjamin, et al.. (2020). Ventral striatum supports Methylphenidate therapeutic effects on impulsive choices expressed in temporal discounting task. Scientific Reports. 10(1). 716–716. 18 indexed citations

3.

Favier, M., Carole Carcenac, Guillaume Drui, et al.. (2017). Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson’s disease. Scientific Reports. 7(1). 41589–41589. 15 indexed citations

4.

Carnicella, Sébastien, Guillaume Drui, Sabrina Boulet, et al.. (2014). Implication of dopamine D3 receptor activation in the reversion of Parkinson’s disease-related motivational deficits. Translational Psychiatry. 4(6). e401–e401. 60 indexed citations

5.

Favier, M., et al.. (2014). Pramipexole reverses Parkinson's disease‐related motivational deficits in rats. Movement Disorders. 29(7). 912–920. 46 indexed citations

6.

Drui, Guillaume, Sébastien Carnicella, Carole Carcenac, et al.. (2013). Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease. Molecular Psychiatry. 19(3). 358–367. 160 indexed citations

7.

Favier, M., Carole Carcenac, Guillaume Drui, et al.. (2013). High-frequency stimulation of the subthalamic nucleus modifies the expression of vesicular glutamate transporters in basal ganglia in a rat model of Parkinson’s disease. BMC Neuroscience. 14(1). 152–152. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact